162 related articles for article (PubMed ID: 27707530)
1. Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia.
Targum SD; Risinger R; Du Y; Pendergrass JC; Jamal HH; Silverman BL
Schizophr Res; 2017 Jan; 179():64-69. PubMed ID: 27707530
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
Meltzer HY; Risinger R; Nasrallah HA; Du Y; Zummo J; Corey L; Bose A; Stankovic S; Silverman BL; Ehrich EW
J Clin Psychiatry; 2015 Aug; 76(8):1085-90. PubMed ID: 26114240
[TBL] [Abstract][Full Text] [Related]
3. Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores.
Ismail Z; Peters-Strickland T; Miguelez M; Baker RA; Hertel P; Eramo A; Jin N; Perry P; Sanchez R; McQuade RD; Kane JM
J Clin Psychopharmacol; 2017 Jun; 37(3):347-350. PubMed ID: 28383362
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation.
Potkin SG; Risinger R; Du Y; Zummo J; Bose A; Silverman B; Stankovic S; Ehrich E
Schizophr Res; 2017 Dec; 190():115-120. PubMed ID: 28342578
[TBL] [Abstract][Full Text] [Related]
5. Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study.
Correll CU; Stanford AD; Claxton A; Du Y; Weiden PJ
Psychiatry Res; 2019 Apr; 274():176-181. PubMed ID: 30802689
[TBL] [Abstract][Full Text] [Related]
6. Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study.
Citrome L; Risinger R; Cutler AJ; Du Y; Zummo J; Nasrallah HA; Silverman BL
CNS Spectr; 2018 Aug; 23(4):284-290. PubMed ID: 28625204
[TBL] [Abstract][Full Text] [Related]
7. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
[No Abstract] [Full Text] [Related]
8. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia.
Citrome L; Du Y; Risinger R; Stankovic S; Claxton A; Zummo J; Bose A; Silverman BL; Ehrich EW
Int Clin Psychopharmacol; 2016 Mar; 31(2):69-75. PubMed ID: 26517202
[TBL] [Abstract][Full Text] [Related]
9. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
[TBL] [Abstract][Full Text] [Related]
10. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial.
Durgam S; Cutler AJ; Lu K; Migliore R; Ruth A; Laszlovszky I; Németh G; Meltzer HY
J Clin Psychiatry; 2015 Dec; 76(12):e1574-82. PubMed ID: 26717533
[TBL] [Abstract][Full Text] [Related]
11. Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study.
Correll CU; Kohegyi E; Zhao C; Baker RA; McQuade R; Salzman PM; Sanchez R; Nyilas M; Carson W
J Am Acad Child Adolesc Psychiatry; 2017 Sep; 56(9):784-792. PubMed ID: 28838583
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate.
Girardi P; Del Casale A; Rapinesi C; Kotzalidis GD; Splendori F; Verzura C; Trovini G; Sorice S; Carrus D; Mancinelli I; Comparelli A; De Filippis S; Francomano A; Ballerini A; Marcellusi A; Mennini FS; Ducci G; Sani G; Pompili M; Brugnoli R
Hum Psychopharmacol; 2018 May; 33(3):e2658. PubMed ID: 29766576
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies.
Cameron C; Zummo J; Desai D; Drake C; Hutton B; Kotb A; Weiden PJ
Curr Med Res Opin; 2018 Apr; 34(4):725-733. PubMed ID: 29179595
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP
CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071
[TBL] [Abstract][Full Text] [Related]
16. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
17. A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil.
Risinger R; Hard M; Weiden PJ
Psychopharmacol Bull; 2017 Aug; 47(3):26-34. PubMed ID: 28839337
[TBL] [Abstract][Full Text] [Related]
18. Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents.
Aggarwal A; Gopalakrishna G; Lauriello J
Clin Schizophr Relat Psychoses; 2016; 10(1):58-63. PubMed ID: 27074333
[TBL] [Abstract][Full Text] [Related]
19. Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil.
Nasrallah HA; Aquila R; Stanford AD; Jamal HH; Weiden PJ; Risinger R
Psychopharmacol Bull; 2017 Aug; 47(3):35-43. PubMed ID: 28839338
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study.
Weiden PJ; Claxton A; Kunovac J; Walling DP; Du Y; Yao B; Yagoda S; Bidollari I; Keane E; Cash E
J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32433835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
